Literature DB >> 9385343

Serological findings in patients with acute syndromes fulfilling the proposed criteria of adult onset Still's disease.

J M Valtonen1, T U Kosunen, J Karjalainen, M Valtonen, M Leirisalo-Repo, V V Valtonen.   

Abstract

In order to analyse possible triggering or contributing infections and HLA-B27 frequency in patients with acute febrile joint syndrome fulfilling the proposed criteria of adult Still's disease (AOSD), we studied prospectively the serological findings of 25 patients. They were aged 15-62 years and diagnosed between 1978-1992. We then compared results with a control group consisting of 119 healthy persons. Positive viral or bacterial serology was found in 12 patients (48%) in the AOSD group compared with 13 cases (11%) in the control group (p < 0.001). Fourfold or higher viral antibody rise was found in two patients and bacterial antibody rise in three patients. High stable viral antibody titre was observed in one patient and high stable bacterial antibody titre in six patients. HLA-B27 was not overrepresented in the study group (12%) compared with a healthy Finnish population (14%). We conclude that many different bacterial and viral infections may trigger or contribute to AOSD.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9385343     DOI: 10.3109/03009749709065695

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  2 in total

1.  [Ankylosing spondylitis associated with Still's disease: should it be considered a pathophysiologic link or a simple association?]

Authors:  Nassira Aradoini; Sofia Talbi; Hamida Azzouzi; Fatima Zahra Abourazzak; Hajar Khibri; Rhizlane Berrady; Wafaa Bono; Taoufik Harzy
Journal:  Pan Afr Med J       Date:  2017-10-10

Review 2.  Roles of Interactions Between Toll-Like Receptors and Their Endogenous Ligands in the Pathogenesis of Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still's Disease.

Authors:  Ju-Yang Jung; Ji-Won Kim; Chang-Hee Suh; Hyoun-Ah Kim
Journal:  Front Immunol       Date:  2020-11-05       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.